Table 4.
Isolate | Year | Country | NAL MIC (mg/L)a | CIP MIC (mg/L)b | GyrB mutation |
---|---|---|---|---|---|
AG-22 | 2004 | Vietnam | 6.0 | 0.250 | Phe-464 |
AS-22541 | 2003 | Bangladesh | 8.0 | 0.125 | Phe-464 |
DT-33 | 2002 | Vietnam | 8.0 | 0.500 | Phe-464 |
DT-94 | 2002 | Vietnam | 16.0 | 0.125 | Phe-464 |
dty1-121 | 1997 | Vietnam | 8.0 | 0.190 | Phe-464 |
E02-2759 | 2002 | India | 4.0 | 0.125 | Phe-464 |
ct 42 | 1994 | Vietnam | 16.0 | 0.160 | Asp-466 |
E98-4364 | 1998 | Mexico | 2.0 | 0.030 | Leu-465 |
aMIC of nalidixic acid (NAL), which ranges from 0.75 to 4.0 mg/L for 25 isolates without mutations.
bMIC of ciprofloxacin (CIP), which ranges from 0.012 to 0.032 mg/L for 25 isolates without mutations.